019170 — SHINPOONG PHARMACEUTICAL CO Income Statement
0.000.00%
- KR₩887bn
- KR₩877bn
- KR₩200bn
- 37
- 10
- 41
- 15
Annual income statement for SHINPOONG PHARMACEUTICAL CO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 189,722 | 197,751 | 189,237 | 209,288 | 200,229 |
Cost of Revenue | |||||
Gross Profit | 76,185 | 76,527 | 77,388 | 77,973 | 80,277 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 184,120 | 190,937 | 203,544 | 245,883 | 247,260 |
Operating Profit | 5,602 | 6,814 | -14,306 | -36,596 | -47,031 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 7,119 | 8,340 | -8,986 | -34,782 | -53,442 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,395 | 5,046 | -11,526 | -35,309 | -57,273 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 5,324 | 5,003 | -11,584 | -35,377 | -57,325 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,080 | 4,774 | -11,165 | -34,034 | -55,127 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 112 | 112 | -227 | -657 | -1,124 |
Dividends per Share |